and by the Belgian Inflammatory Bowel Disease Research and Development Grant 2023. JS and TV are supported by a senior ...

Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, ...

Aeglea Biotherapeutics Inc. ( (SYRE) ) has released its Q3 earnings. Here is a breakdown of the information Aeglea Biotherapeutics Inc.

Abu Dhabi, UAE: Sheikh Shakhbout Medical City (SSMC), one of the UAE’s largest hospitals for serious and complex care and a ...

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...

Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.

A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process.

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...

The first patient has been dosed in Microbiotica’s Phase 1b first-in-human trial, COMPOSER-1, of MB310.

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error ...